key: cord-0854069-gefg4t2o
authors: Mohandas, Sreelekshmy; Yadav, Pragya D; Nyayanit, Dimpal; Deshpande, Gururaj; Shete-Aich, Anita; Sapkal, Gajanan; Kumar, Sanjay; Jain, Rajlaxmi; Kadam, Manoj; Kumar, Abhimanyu; Patil, Deepak Y; Sarkale, Prasad; Gawande, Pranita; Abraham, Priya
title: Comparison of the pathogenicity and virus shedding of SARS CoV-2 VOC 202012/01 and D614G variant in hamster model
date: 2021-02-25
journal: bioRxiv
DOI: 10.1101/2021.02.25.432136
sha: dbfbbed49c46fa23adf4bc479388c27aef00c83f
doc_id: 854069
cord_uid: gefg4t2o

The emergence of SARS-CoV-2 variants has posed a serious challenge to public health system and vaccination programs across the globe. We have studied the pathogenicity and virus shedding pattern of the SARS-CoV-2 VOC 202012/01 and compared with D614G variant in Syrian hamsters. VOC 202012/01 could produce disease in hamsters characterized by body weight loss and respiratory tract tropism but mild lung pathology. Further, we also documented that neutralizing antibodies developed against VOC 202012/01 could equally neutralize D614G variant. Higher load of VOC 202012/01 in the nasal wash specimens was observed during the first week of infection outcompeting the D614G variant. The findings suggest increased fitness of VOC 202012/01 to the upper respiratory tract which could lead to higher transmission. Further investigations are needed to understand the transmissibility of new variants. One-Sentence Summary SARS-CoV-2 VOC 202012/01 infected hamsters demonstrated high viral RNA shedding through the nasal secretions and significant body weight loss with mild lung pathology compared to the D614G variant.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has significantly impacted the global healthcare and economy (1) . Rapid spread of the virus, non-availability of any treatment or vaccines and insufficient healthcare facilities posed challenges in the beginning 5 of the pandemic. Research on development of countermeasures against the disease was initiated in no time and now several vaccines are available across the globe like BNT162b2, mRNA-1273, ChAdOx1-S [recombinant], COVAXIN etc. (2, 3). The high mutation rate in RNA viruses helps them swiftly adapt to diverse environmental conditions posing a greater challenge in their prevention and control (4, 5) . The continuous genomic surveillance of the circulating SARS- 10 CoV-2 worldwide has given us clues about the genetic mutations acquired by the virus. The identification of such variants with potential of high transmission, disease severity, immunity evasion, resistance to therapeutic measures and ability to evade diagnostic tests is imperative to control the pandemic (6). Recently, various new SARS-CoV-2 variants have been reported worldwide which are of serious concern (7, 8) . 15 SARS-CoV-2 is a single-stranded, positive-sense RNA virus that belongs to the genus Betacoronavirus of the Coronaviridae family. Its genome size is approximately 30 kbps, encoding different structural and non-structural proteins essential for the virus (9) . The SARS-CoV-2 strains circulating during the early pandemics have been superseded with new variant strains (7, 10) . Initially, SARS-CoV-2 strains with D614G mutation in the spike glycoprotein 20 became predominant worldwide (11) . This strain was associated with high viral loads in the upper respiratory tract than the earlier strains but didn't produce severe disease (12). Recently, various viral strains of SARS-CoV-2 with mutations of concern like VOC 202012/01 (B.1.1.7 5 transmission in at least 47 countries (7, 13) . This variant has amino acid changes in the spike protein that included deletions (69/70,144Y) and replacements (N501Y, A570D, D614G, and P681H). The N501Y mutation in the Receptor Binding Domain (RBD) has been found to increase the binding affinity to Angiotensin Converting Enzyme 2 receptor by 10 times higher than that of the wild type RBD, which could increase the infectivity and transmissibility of the 10 virus (14) . Amino acid at position 501 which is in the RBD can possibly affect the efficacy of virus neutralization too as RBD accounts for 90% neutralizing activity against SARS-CoV-2 (15) . The cumulative effect of all these mutations are still unknown and the initial reports from phylogenetic and transmission model analysis indicated that some of these mutations may influence the transmissibility of the virus in humans (16 

Twenty Syrian hamsters were inoculated intranasally with 10 4.5 TCID 50 dose of SARS-CoV-2 10 VOC-202012/01 ['hCoV-19/India/NIVP1 20203522/2020" (GISAID identifier:

EPL_ISL_825088)] to determine its pathogenicity ( Fig 1A) . The infected hamsters demonstrated body weight loss with no apparent clinical signs ( 

The infected animals exhibited anti-SARS-CoV-2 IgG response from 7 th DPI which persisted till day 14 (Fig 2A-C) . The response was found predominantly of IgG2 type. The serum samples of the infected hamsters were checked for their neutralization ability against both homologous (VOC-202012/01) and heterologous (D614G variant) SARS-CoV-2 strains. Although on 5 DPI, 10 the neutralization titer differed significantly with a higher titer against the VOC 202012/01, the Fig 2D) . 

The respiratory tract tropism of the virus was evident with the high viral genomic RNA (gRNA) 

On gross examination of organs during necropsy, lungs showed congestive changes and hemorrhagic foci of multiple sizes from 5 DPI which persisted till 10 DPI (Fig 4A) . (Table S1 ) (20) . Congestion and hemorrhages were observed 10 as early as 3 DPI in D614G variant infected animals and more pronounced alveolar septal thickening, consolidation and inflammatory infiltration were also observed (4E, F). 

We have assessed the serum cytokine levels in the infected hamsters on 3, 7 and 14 DPI and compared with SARS-CoV-2 D614G variant from an earlier study where hamsters were intranasally infected with 10 5.5 TCID50/ml of the virus. But no significant difference could be observed in the cytokine levels in hamsters infected with both variants (Fig.S1 ). 15 

We inoculated six hamsters each intranasally with (Fig 4E-F) . The gRNA loads in the nasal wash samples were significantly high on 4, 6 and 8 DPI (Fig. 4C) . Virus titration performed on throat swab and nasal wash samples till 10 DPI demonstrated the persistent virus titer and no statistical significance in virus titer was observed among the two variants (Fig. S2 ). significance was assessed using the non-parametric Mann-Whitney test between the two groups;

p-values less than 0.05 were considered to be statistically significant.

Considering the worldwide concern and speculation of the high transmission and disease severity related to VOC20212/01, we assessed the disease severity and virus shedding pattern of VOC In our earlier study with SARS-CoV-2 D614G variant in hamsters, the peak gRNA load in lungs 15 and nasal turbinate was detected on 3 DPI and further decrease on subsequent days (22) . Here, 

Figs. S1 to S2 5 Table S1 

Twenty-four (12 male and 12 female) Syrian hamsters of 8-10-week-old age were used for the pathogenicity experiment. The hamsters were housed in individually ventilated cages with ad libitum food and water. Twenty hamsters were challenged with 0.1 ml of 10 5.5 TCID50/ml 20 Nasal wash, throat swab and faecal samples were collected from hamsters in 1ml viral transport medium. Organ samples were weighed and triturated in 1 ml sterile tissue culture media using a tissue homogenizer (Eppendorf, Germany). Two hundred microliters of the tissue homogenate/ swab specimens were used for RNA extraction using MagMAX™ Viral/Pathogen Nucleic Acid 

The lungs, nasal turbinate, throat swab and nasal wash samples were used for virus titration in and Muench method and were expressed at TCID50/ml (33) . The serum samples collected on day 3, 5, 7, 10 and 14 DPI were tested for IgG antibodies by hamster anti-SARS-CoV-2 IgG ELISA. The assay procedure in brief is as follows. Ninety-six well microtiter plates were coated with inactivated SARS-CoV-2 antigen in carbonate buffer of pH 9.5 overnight at 4 °C. The wells were blocked with liquid plate sealer for two hours at room temperature (25-30°C) and further washed with phosphate-buffered saline with 0.05% Tween 20 5 (PBS-T). The plates were incubated at 37°C for one hour with 100μl of diluted hamster serum samples (1: 100). After 5 washes with PBS-T, anti-hamster IgG-horse radish peroxidase1:3000 (Thermoscientific, USA) were added and incubated for 1 hour at 37°C. The plate was washed with PBS-T for five times. Hundred μ l of substrate, 3',3'5,5'-tetramethylbenzidine (TMB) was added to each well following the wash. Absorbance was measured at 450 nm following the 10 termination of color developed. Optical density of more than 0.2 and positive/negative (P/N) ratio above 1.5 was considered positive. For antibody sub-typing, the same protocol was followed except that of the use of biotinylated anti-Syrian hamster IgG1 /IgG2 antibodies in 1:10000 dilution (BD biosciences, USA) and Streptavidin-horseradish peroxidase 1:8000 (Thermo-scientific, USA) for detection. 15 

The assay was performed using hamster serum samples collected on 3 Lungs samples collected during necropsy were fixed in 10% neutral buffered formalin. The tissues were processed using an automated tissue processor. The processed tissues were embedded in paraffin and were sectioned using an automated microtome (Leica, Germany) and

were stained by hematoxylin and eosin staining.

Serum cytokine analysis 10 The serum cytokine levels (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α and IL-12) were assessed in hamsters serum samples collected at 3, 7 and 14 DPI. A commercial ELISA (Immunotag, USA) was used for the hamster specific cytokine quantitation. For this, plates precoated with hamster specific cytokine antibody were used and a streptavidin based HRP system was used for detection. The absorbance was measured at 450 nm. 15 

For analysis of the data, Graph pad Prism version 8.4.3 software was used. For statistical analysis; non parametric Mann Whitney tests were used and the p-values less than 0.05 were considered to be statistically significant. 

Impact of COVID-19 on people's livelihoods, their health and our food systems

Submitted Manuscript: Confidential Template revised

Different COVID-19 Vaccines

Worldwide COVID-19 candidate vaccines. COVID-19 vaccines undertrials in India

Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity

Genomic Analysis of the Emergence, Evolution, and Spread of Human Respiratory RNA Viruses

Investigation of novel SARS-COV-2 variant. Variant of Concern 202012/01

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

A pneumonia outbreak associated with a new 10 coronavirus of probable bat origin

Understanding variants of SARS-CoV-2

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Emergence of a Highly Fit SARS-CoV-2 Variant

Submitted Manuscript: Confidential Template revised

Weekly epidemiological update -2

The basis of a more contagious 501Y. V1 variant of SARS-5 COV-2

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Submitted Manuscript: Confidential Template revised

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection 5 with Virus Shedding in Golden Syrian Hamsters

First isolation of SARS-CoV-2 from clinical samples in India

Isolation and characterization of VUI-202012/01, a SARS-CoV-2 variant in travellers from the United Kingdom to India

Compendium of CPCSEA 2018 (Committee for the Purpose of Control and Supervision of Experiments on Animals

Development of in vitro transcribed RNA as positive control for laboratory diagnosis of 20 SARS-CoV-2 in India

Submitted Manuscript: Confidential Template revised

Virological assessment of hospitalized patients with COVID-2019

A simple method of estimating fifty per cent endpoints

Acknowledgments: The authors acknowledge the support received from Dr Chandrasekhar

Dilip Patil, Scientist D, ICMR-NIV, Pune and the laboratory team of Maximum Containment Facility, ICMR-NIV, Pune which includes Mr

Funding: The authors acknowledge the financial support provided by the Indian Council of 15

Confidential Template revised February 2021 31 Supervision: PDY, SM, GS, ASA Writing -original draft: PDY, SM Writing -review & editing

Competing interests: Authors declare that they have no competing interests.Data and materials availability: All data are available in the main text or the supplementary